Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway.
about
Human retroviral host restriction factors APOBEC3G and APOBEC3F localize to mRNA processing bodiesThe dimerization domain of HIV-1 viral infectivity factor Vif is required to block virion incorporation of APOBEC3GHIV-1 replication and APOBEC3 antiviral activity are not regulated by P bodiesAPOBEC3A, APOBEC3B, and APOBEC3H haplotype 2 restrict human T-lymphotropic virus type 1Sole copy of Z2-type human cytidine deaminase APOBEC3H has inhibitory activity against retrotransposons and HIV-1Differential sensitivity of murine leukemia virus to APOBEC3-mediated inhibition is governed by virion exclusion.Human immunodeficiency virus type 1 Vpr induces the degradation of the UNG and SMUG uracil-DNA glycosylasesRole and mechanism of action of the APOBEC3 family of antiretroviral resistance factorsHIV-1 Vif and APOBEC3G: multiple roads to one goalA second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteinsA single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletionDifferential anti-APOBEC3G activity of HIV-1 Vif proteins derived from different subtypesHIV-1 Vif versus the APOBEC3 cytidine deaminases: an intracellular duel between pathogen and host restriction factorsHIV-1 Vif, APOBEC, and intrinsic immunityStructure, interaction and real-time monitoring of the enzymatic reaction of wild-type APOBEC3GCytidine deamination induced HIV-1 drug resistanceThe HIV-1 Vif PPLP motif is necessary for human APOBEC3G binding and degradationInhibition of tRNA₃(Lys)-primed reverse transcription by human APOBEC3G during human immunodeficiency virus type 1 replicationIdentification of amino acid residues in APOBEC3G required for regulation by human immunodeficiency virus type 1 Vif and Virion encapsidationHuman immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integrationProduction of infectious human immunodeficiency virus type 1 does not require depletion of APOBEC3G from virus-producing cellsNatural variation in Vif: differential impact on APOBEC3G/3F and a potential role in HIV-1 diversificationDual inhibitory effects of APOBEC family proteins on retrotransposition of mammalian endogenous retrovirusesHIV Genome-Wide Protein Associations: a Review of 30 Years of ResearchViral Mimicry to Usurp Ubiquitin and SUMO Host PathwaysMultiple APOBEC3 restriction factors for HIV-1 and one Vif to rule them allThe APOBEC3 family of retroelement restriction factorsThe Cellular Antiviral Protein Viperin Is Attenuated by Proteasome-Mediated Protein Degradation in Japanese Encephalitis Virus-Infected CellsInsight into the HIV-1 Vif SOCS-box-ElonginBC interactionCullin4A and cullin4B are interchangeable for HIV Vpr and Vpx action through the CRL4 ubiquitin ligase complexReversed functional organization of mouse and human APOBEC3 cytidine deaminase domainsNewly synthesized APOBEC3G is incorporated into HIV virions, inhibited by HIV RNA, and subsequently activated by RNase HMulti-scale modeling of HIV infection in vitro and APOBEC3G-based anti-retroviral therapyInhibition of a NEDD8 Cascade Restores Restriction of HIV by APOBEC3GAPOBEC3G: an intracellular centurionParadigm development: comparative and predictive 3D modeling of HIV-1 Virion Infectivity Factor (Vif).Multiple ways of targeting APOBEC3-virion infectivity factor interactions for anti-HIV-1 drug development.The inhibition of assembly of HIV-1 virus-like particles by 3-O-(3',3'-dimethylsuccinyl) betulinic acid (DSB) is counteracted by Vif and requires its Zinc-binding domain.Molecular insight into the conformational dynamics of the Elongin BC complex and its interaction with HIV-1 Vif.Polymorphisms of CUL5 are associated with CD4+ T cell loss in HIV-1 infected individuals.
P2860
Q21090536-424FC689-AF1B-4401-A6EE-5C3FA4D7D11EQ21245195-06761206-95A7-45FF-8FEB-201885A8EDFDQ24297395-0DF24D7C-424B-46AB-A1E0-46106669A4F8Q24310242-B4DDC9A4-E103-4D9B-88AC-871884C76CD6Q24317568-AD2DD18E-49D3-40FD-AC13-49EC25BD2A08Q24529150-FA4AD07F-69F4-4EB9-AF32-7A91FC272C4CQ24530147-AC1E9010-94CB-453E-81CC-4B15D17001D8Q24537623-7A501888-CADA-4DBA-973C-74CAA8F37B6AQ24564072-E59CD04E-D016-475E-A8C4-A7FC3A96C133Q24564187-0AEE5118-13F5-4340-8F3B-CDC7D20EB53AQ24568052-49196F5A-E6CC-43EC-AD75-85C6F45D243DQ24612992-CD30AA6E-CBD7-48AA-A3C4-D00FE5AD3B94Q24619114-26E9959D-8095-416F-9285-523706465860Q24647833-43196F8A-F22A-4C77-9F41-DB88A7E050FAQ24649945-A314819C-869D-4C47-A94B-E645E6A33C0BQ24657298-67043E82-1349-4215-87CC-D5E1D391BDC5Q24657375-617E11B6-4AB2-4AB8-A5D1-724F00D43901Q24669993-6CCCF3A8-04DC-4F7D-B197-6E07D40A819CQ24672209-6394E4DC-5590-40B8-B8D2-AB4E1A06D58DQ24684279-D7614B5C-B8C9-4164-98D2-33CAC20F667EQ24796626-5AF84A9C-47F9-4058-96E6-10C208366B04Q24817186-24387CEE-B5A1-47A5-BF5E-299DC9C96242Q25257798-079FCE7C-E551-43A1-9A7C-7895C48221C8Q26746070-4B6A3ECC-2B4C-4CCB-95CE-B5B2296C6A0FQ26783655-F6356A3C-491D-41CF-948D-3B5DE1003E9CQ26823568-7C412FC6-F8B7-4F4E-8902-B9C83E3E8423Q26862780-BEA24ACF-9495-4C0A-8E9D-83743D80630CQ27487126-D56CD74D-B7DF-4699-BF04-D371FF7CB30CQ27680599-5E16B4F8-741A-40CF-8BEB-3BEAFDCA3EB2Q28237912-2BB53279-268A-4E25-B920-333723496550Q28266980-2111DDC9-DD08-4C7C-B7EA-320775C9F185Q28469134-563A6DF7-E433-45AA-9A41-93DC27BD67E6Q28480578-DEF55A0E-8093-494A-89F4-FB21283756D8Q28484619-416CAB84-F331-447F-98F4-DDCAEF59712DQ28754989-609683BE-1BE4-4F56-9DA9-D940DA3969D4Q30362641-AB175D8A-8CF4-4E5C-9F22-508C951BF870Q30381745-2314DDE6-1D3F-436E-8602-A8071A9F7CDEQ30440445-0D6B41C0-A78C-43A4-A328-07A08087BCF3Q30496853-BB706071-9AC9-403B-93B4-4CAB7804BF0FQ33270513-07FC34A0-F345-448A-9878-FA92DAA78242
P2860
Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Vif overcomes the innate antiv ...... ubiquitin-proteasome pathway.
@en
type
label
Vif overcomes the innate antiv ...... ubiquitin-proteasome pathway.
@en
prefLabel
Vif overcomes the innate antiv ...... ubiquitin-proteasome pathway.
@en
P2093
P356
P1476
Vif overcomes the innate antiv ...... ubiquitin-proteasome pathway.
@en
P2093
Andrew Mehle
Bettina Strack
Chengsheng Zhang
Dana Gabuzda
Mark McPike
Petronela Ancuta
P304
P356
10.1074/JBC.M313093200
P407
P577
2003-12-13T00:00:00Z